摘要
宝那替尼是第三代激酶抑制剂,旨在克服守门人T315I突变。在不同的试验中,该药物对天然bcr-abl 1激酶有抑制作用。ABL 1突变由于这个原因,目前已表明,在抵抗和/或不耐大司替尼和尼洛替尼的疾病的各个阶段治疗慢性粒细胞白血病(Cml)。而伊马替尼不再被用于治疗T315I突变的患者。该药物也适用于Ph急性淋巴细胞白血病(ALL)。宝那替尼于2013年暂停使用心血管血栓事件的发生。从那时起,不同的研究者分析了普拉替尼患者的基线特征,特别是心血管方面的特征,n说明在这种情况下的一般管理建议。 在这篇综述中,我们将讨论帕纳替尼在CML和Ph所有患者中的临床试验数据。它也将重点关注药物的安全性和耐受性概况以及未来。就业前景。
关键词: 慢性髓系白血病,Ph急性淋巴细胞白血病,扎那替尼,T315I突变,心血管事件,佩斯试验,EPIC试验。
图形摘要
Current Cancer Drug Targets
Title:Ponatinib: A Review of Efficacy and Safety
Volume: 18 Issue: 9
关键词: 慢性髓系白血病,Ph急性淋巴细胞白血病,扎那替尼,T315I突变,心血管事件,佩斯试验,EPIC试验。
摘要: Ponatinib is a third generation kinase inhibitor designed to overcome the gatekeeper T315I mutation. In different trials this drug showed inhibitory activity against native BCR-ABL1 kinase and several ABL1 mutations. For this reason, ponatinib is currently indicated for the treatment of chronic myeloid leukaemia (CML) in every phase of disease resistant and/or intolerant to dasatinib and nilotinib and for whom imatinib is not indicated anymore or for patients with T315I mutation. The drug is also indicated for Ph+ acute lymphoblastic leukaemia (ALL). Ponatinib was temporarily suspended in 2013 for the occurrence of cardiovascular thrombotic events. Since then, different investigators analyzed baseline characteristics of patient candidates for ponatinib, especially cardiovascular profile, in order to describe general management recommendations in this setting.
In this review, clinical trials data about the use of ponatinib in CML and Ph+ ALL patients will be discussed. It will be focused also about the safety and tolerability profile of the drug and future perspectives of employment.
Export Options
About this article
Cite this article as:
Ponatinib: A Review of Efficacy and Safety, Current Cancer Drug Targets 2018; 18 (9) . https://dx.doi.org/10.2174/1568009617666171002142659
DOI https://dx.doi.org/10.2174/1568009617666171002142659 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview of Naturally Occurring Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Current Pharmaceutical Design Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Novel Drug Targets in Malaria Parasite with Potential to Yield Antimalarial Drugs with Long Useful Therapeutic Lives
Current Pharmaceutical Design The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms and Proposed Targets for Selected Anticancer Gold Compounds
Current Topics in Medicinal Chemistry Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Gastrin: An Acid-Releasing, Proliferative and Immunomodulatory Peptide?
Mini-Reviews in Medicinal Chemistry Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Current Vascular Pharmacology Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Current Pharmaceutical Biotechnology Innate Immunity and Intracellular Trafficking: Insights for Novel Anti- HIV-1 Therapeutics
Current Pharmacogenomics Resistance in Cancer: A Target for Drug Discovery
Current Medicinal Chemistry - Anti-Cancer Agents New Antitumour Natural Products from Marine Red Algae: Covering the Period from 2003 to 2012
Mini-Reviews in Medicinal Chemistry Synthesis and Antiproliferative Evaluation of Spirothiadiazolopyridazine Derivatives
Letters in Drug Design & Discovery